Sangamo Therapeutics Inc (SGMO) VP Edward R. Conner Sells 5,000 Shares

Sangamo Therapeutics Inc (NASDAQ:SGMO) VP Edward R. Conner sold 5,000 shares of the stock in a transaction that occurred on Tuesday, November 6th. The shares were sold at an average price of $13.73, for a total value of $68,650.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Edward R. Conner also recently made the following trade(s):

  • On Monday, October 8th, Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $14.55, for a total value of $72,750.00.
  • On Thursday, September 6th, Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $14.17, for a total value of $70,850.00.

Shares of SGMO traded down $0.46 during mid-day trading on Thursday, hitting $13.84. The company’s stock had a trading volume of 43,506 shares, compared to its average volume of 1,609,804. Sangamo Therapeutics Inc has a one year low of $11.65 and a one year high of $27.50. The company has a current ratio of 7.24, a quick ratio of 7.24 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -19.91 and a beta of 3.21.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. The business had revenue of $21.42 million during the quarter, compared to the consensus estimate of $21.43 million. During the same period in the prior year, the company posted ($0.17) earnings per share. The firm’s revenue was up 159.6% compared to the same quarter last year. Equities analysts predict that Sangamo Therapeutics Inc will post -0.69 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of SGMO. BlackRock Inc. boosted its position in shares of Sangamo Therapeutics by 20.8% in the second quarter. BlackRock Inc. now owns 8,083,121 shares of the biopharmaceutical company’s stock valued at $114,780,000 after acquiring an additional 1,391,067 shares during the period. Wasatch Advisors Inc. boosted its position in shares of Sangamo Therapeutics by 12.0% in the third quarter. Wasatch Advisors Inc. now owns 4,544,596 shares of the biopharmaceutical company’s stock valued at $77,031,000 after acquiring an additional 486,429 shares during the period. Handelsbanken Fonder AB bought a new stake in shares of Sangamo Therapeutics in the second quarter valued at approximately $5,069,000. Nexthera Capital LP boosted its position in shares of Sangamo Therapeutics by 35.7% in the second quarter. Nexthera Capital LP now owns 1,066,914 shares of the biopharmaceutical company’s stock valued at $15,150,000 after acquiring an additional 280,538 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of Sangamo Therapeutics by 42.2% in the second quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock valued at $11,218,000 after acquiring an additional 234,346 shares during the period. 64.01% of the stock is owned by institutional investors.

Several equities analysts have commented on SGMO shares. BidaskClub upgraded Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 2nd. Cowen reiterated a “buy” rating on shares of Sangamo Therapeutics in a report on Monday, July 23rd. Zacks Investment Research upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 14th. ValuEngine downgraded Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, September 6th. Finally, Wedbush reissued a “hold” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Sangamo Therapeutics has a consensus rating of “Buy” and an average target price of $21.00.

TRADEMARK VIOLATION NOTICE: This article was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.wkrb13.com/2018/11/08/sangamo-therapeutics-inc-sgmo-vp-edward-r-conner-sells-5000-shares.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Featured Story: Google Finance Portfolio

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply